RecruitingPhase 2NCT06386315
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Bradford S. Hoppe, MD, MPHMayo Clinic
- Intervention
- Computed Tomography(procedure)
- Enrollment
- 112 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (7)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States
- Mayo Clinic Health System - Mankato, Mankato, Minnesota, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06386315 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah
- RECRUITINGPHASE2NCT07030699A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasH. Lee Moffitt Cancer Center and Research Institute